EOLS241018C17500
- 0.25
- -0.20-44.44%
Evolus Newsroom
Evolus Down Nearly 6%, on Pace for Largest Percent Decrease Since August 2023 -- Data Talk
Evolus Is Maintained at Overweight by Barclays
Analyst Scoreboard: 4 Ratings For Evolus
Stifel Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $25
Stifel analyst Annabel Samimy maintains $Evolus(EOLS.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 45.1% and a total
Stifel Nicolaus Reaffirms Their Buy Rating on Evolus (EOLS)
When Will Evolus, Inc. (NASDAQ:EOLS) Breakeven?
Needham Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $22
Needham analyst Serge Belanger maintains $Evolus(EOLS.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 41.6% and a total
Evolus Buy Rating Justified by Strong Market Positioning and Growth Projections
Express News | Evolus Inc : Mizuho Raises Target Price to $25 From $23
Barclays Maintains Evolus(EOLS.US) With Buy Rating, Raises Target Price to $20
Barclays analyst Balaji Prasad maintains $Evolus(EOLS.US)$ with a buy rating, and adjusts the target price from $16 to $20.According to TipRanks data, the analyst has a success rate of 47.2% and a
Mizuho Securities Maintains Evolus(EOLS.US) With Buy Rating, Maintains Target Price $23
Mizuho Securities analyst Uy Ear maintains $Evolus(EOLS.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 40.4% and a total
Cantor Fitzgerald Reiterates Overweight on Evolus
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024
Why Investors Shouldn't Be Surprised By Evolus, Inc.'s (NASDAQ:EOLS) 27% Share Price Surge
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus, Inc. (EOLS): Is It One of Caligan Partners' Top Holdings Now?
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Evolus (EOLS) and Humana (HUM)
Evolus, Inc. (NASDAQ:EOLS) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Evolus Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Evolus Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results and Raised Its FY24 Revenue Guidance.